Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMTAS
2017-004162-99Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in colorectal cancer (CRC) comparing Ramucirumab + TAS102 with TAS102 monotherapy (2 arms). Primary endpoint: Overall survival. Started Apr 2018; status: completed.
02
Drugs
ramucirumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-004162-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004162-99.